Green Star Products Signs Covid-19 Distribution Contract
SALT LAKE CITY, UT, Dec. 14, 2020 (GLOBE NEWSWIRE) Last Friday, December 11, 2020, Joseph LaStella, President of Green Star Products, Inc. (OTC: GSPI) announced he signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries.
VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus
in vitro.
VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses
Share:
SALT LAKE CITY, UT, Dec. 11, 2020 (GLOBE NEWSWIRE) Today, Joseph LaStella, President of Green Star Products, Inc. (OTC:GSPI) announced he has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries.
VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus
in vitro.
VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses
in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic